Home > Journals > Minerva Medica > Past Issues > Articles online first > Minerva Medica 2021 Feb 12



To subscribe
Submit an article
Recommend to your librarian


Publication history
Cite this article as



Minerva Medica 2021 Feb 12

DOI: 10.23736/S0026-4806.21.07379-1


language: English

Baseline, procedural and outcome features of patients undergoing transcatheter aortic valve implantation according to different body mass index categories

Nicola CORCIONE 1, Alberto TESTA 2, Paolo FERRARO 3, Alberto MORELLO 1, Michele CIMMINO 1, Michele ALBANESE 3, Salvatore GIORDANO 1, Francesco BEDOGNI 4, Alessandro IADANZA 5, Sergio BERTI 6, Damiano REGAZZOLI 7, Carlo TRANI 8, Martino PEPE 9, Giacomo FRATI 10, 11, Giuseppe BIONDI-ZOCCAI 10, 12 , Arturo GIORDANO 1, on behalf of the Registro Italiano GISE sull'impianto di Valvola Aortica Percutanea (RISPEVA) Study Investigators

1 Unità Operativa di Interventistica Cardiovascolare, Pineta Grande Hospital, Castel Volturno, Caserta, Italy; 2 Sapienza University of Rome, Rome, Italy; 3 Unità Operativa di Emodinamica, Santa Lucia Hospital, San Giuseppe Vesuviano, Napoli, Italy; 4 Department of Cardiology, IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy; 5 Divisione di Emodinamica, Dipartimento di Scienze Cardiache, Toraciche e Vascolari, Policlinico Santa Maria alle Scotte, Siena, Italy; 6 Fondazione C.N.R. G. Monasterio Ospedale del Cuore, Massa, Italy; 7 Cardio Center, IRCCS Humanitas Research Center, Rozzano, Milan, Italy; 8 Institute of Cardiology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy; 9 Division of Cardiology, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy; 10 Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy; 11 IRCCS NEUROMED, Pozzili, Isernia, Italy; 12 Mediterranea Cardiocentro, Napoli, Italy

BACKGROUND: Transcatheter aortic valve implantation (TAVI) has become first-line treatment for severe aortic valve stenosis in patients with moderate, high or prohibitive surgical risk.. However, access site complications may occur more frequently in such extreme body mass index (BMI) categories,. We aimed at describing features and outcomes of patients undergoing TAVI in a comprehensive Italian prospective clinical registry.
METHODS: A national prospective database was queried for baseline, procedural, and outcome details of patients undergoing TAVI according to established BMI classes: underweight (BMI <18.5 kg/m2), normal weight (BMI 18.5-24.9 kg/m2), overweight (BMI 25.0-29.9 kg/m2), and obese (BMI ≥30 kg/m2). Short- and long-term outcomes, including major adverse events (MAE), i.e. the composite of death, stroke, myocardial infarction, major vascular complication, major bleeding, or renal failure, were appraised with bivariate and multivariable analyses.
RESULTS: A total of 3075 subjects were included, 64 (2.1%) were underweight, 1319 (42.9%) were normal weight, 1152 (37.4%) were overweight, and 540 (17.6%) were obese. Several baseline differences were evident, including gender, diabetes mellitus, renal function, chronic obstructive pulmonary disease, surgical scores, and left ventricular ejection fraction (LVEF) (all p<0.05). Several procedural differences were also evident, including percutaneous approach, predilation, prosthesis type and size (all p<0.05), with postprocedura aortic regurgitation >2+ significantly more common in underweight patients (p<0.05). Nonetheless, unadjusted analysis for one-month outcomes showed similar rates for fatal and non-fatal outcomes, including MAE (all p>0.05), with the notable exception of permanent pacemaker implantation, which was more common in higher BMI classes (p=0.010) Unadjusted analysis for long-term events showed an increased rate of death in underweight patients (p=0.024). Multivariable adjusted analysis confirmed the increased risk of permanent pacemaker implantation in obese patients (p=0.015 when comparing obese vs normal weight subjects), but disproved differences in mortality (p>0.05 for all comparisons).
CONCLUSIONS: Irrespective of BMI class, TAVI is associated with favorable outcomes in surgical high-risk risk patients, with the notable exclusion of permanent pacemaker implantation, which is significantly more common in obese subjects.

KEY WORDS: Aortic stenosis; Body mass index; Cachexy; Obesity; Overweight; Transcatheter aortic valve implantation; Transcatheter aortic valve replacement; Underweight

top of page